127 related articles for article (PubMed ID: 38432672)
1. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
4. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Ishii M; Itano O; Morinaga J; Shirakawa H; Itano S
PLoS One; 2022; 17(4):e0266707. PubMed ID: 35452492
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
6. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Huang P; Huang X; Zhou Y; Yang G; Sun Q; Shi G; Chen Y
Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
[TBL] [Abstract][Full Text] [Related]
8. Systemic Chemotherapy with or without Hepatic Arterial Infusion Chemotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Oligometastasis: A Propensity Score-Matched Analysis.
Li Z; Xu R; Chang X; Sun P
J Vasc Interv Radiol; 2024 Mar; 35(3):416-427.e17. PubMed ID: 38008375
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
[TBL] [Abstract][Full Text] [Related]
10. Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety.
Li L; Liu S; Wang Q; Wang Y; Yu G
J Cancer Res Ther; 2024 Apr; 20(2):578-583. PubMed ID: 38687927
[TBL] [Abstract][Full Text] [Related]
11. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
13. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
Jiang N; Zhang Z; Yin X; Qiu H; Yan W; Hao Y; Yang W; Li H; Xu A; Mu K
Radiol Med; 2024 Apr; 129(4):631-642. PubMed ID: 38355907
[TBL] [Abstract][Full Text] [Related]
14. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
Lai Z; Huang Y; Wen D; Lin X; Kan A; Li Q; Wei W; Chen M; Xu L; He M; Shi M
BMC Med; 2022 Oct; 20(1):415. PubMed ID: 36310160
[TBL] [Abstract][Full Text] [Related]
15. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
16. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety.
Liu D; Wang J; Ma Z; Zhang N; Zhao Y; Yang X; Wen Z; Xie H
Cardiovasc Intervent Radiol; 2022 Aug; 45(8):1092-1101. PubMed ID: 35588011
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
19. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Konstantinidis IT; Do RK; Gultekin DH; Gönen M; Schwartz LH; Fong Y; Allen PJ; D'Angelica MI; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Ann Surg Oncol; 2014 Aug; 21(8):2675-83. PubMed ID: 24664624
[TBL] [Abstract][Full Text] [Related]
20. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
